News and Press Releases
Have you missed any of our press releases or news? No problem – all recently released information is still available in our news archive.
+ Read more
In case there are still questions from your side, we are looking forward to your messages sent via the contact form on the bottom of the page.
News Archive
05/05/2020
Eckert & Ziegler Eurotope GmbH successfully passes interim audit for ISO 9001 certification
Berlin, Germany
Eckert & Ziegler Eurotope’s quality management has again been audited and certified to the ISO 9001 standard. At the beginning of March an interim audit by TÜV was successfully passed. The certification is valid for another year until the system will undergo a more extensive re-audit early … Read more
30/03/2020
Eckert & Ziegler joins Nuclear Medicine Europe - the industry association
Berlin
Nuclear Medicine Europe (NMEu) and its members unanimously approved Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) as the latest member of the industrial association. Joining the ranks of the major nuclear medicine tracer companies and equipment manufacturers, Eckert & Ziegler will … Read more
23/03/2020
COVID-19 measures – We take care and are there for you
The whole world is experiencing a completely new and difficult situation. COVID-19 is one of the most challenging things that we have experienced in the last decades and our thoughts are with the ones affected as well as their families.
In this time of uncertainty, we are closely following the … Read more
05/03/2020
Eckert & Ziegler Starts Commercial Production of Lutetium-177
Berlin
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) has developed a new technology for the production of carrier-free lutetium-177. It is based on the irradiation of ytterbium-176 and the subsequent separation of the resulting lutetium-177 in a radiochemical facility. The … Read more
02/03/2020
Eckert & Ziegler to Financially Back Clinical Development of Innovative Lymphoma Treatment
Berlin
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) will financially support the clinical development of two proprietary new radiopharmaceuticals for the diagnosis and treatment of malignant lymphomas. The Board of Directors today approved a first payment of 3 mm EUR in … Read more
12/02/2020
Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis
Berlin
The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) and the Israeli Isotopia Molecular Imaging Ltd. (Isotopia) will in future work more closely together in the early detection of prostate cancer and to this end recently concluded an agreement on the joint … Read more
03/02/2020
Eckert & Ziegler to Open up US-Production Site for Yttrium-90
Berlin
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) will open up a radiopharmaceutical production site in the Boston area and has signed a long-term rental contract for a suitable building in Wilmington, Massachusetts. Mirroring the technology of Eckert & Ziegler’s … Read more
06/12/2019
Eckert & Ziegler's cassette production successfully expanded
Berlin
Eckert & Ziegler successfully completed construction of an additional cleanroom for the assembly of their synthesis cassettes. This expansion of the production capacities will ensure, that future demands can be satisfied while meeting the same high quality standard that Eckert & … Read more
29/08/2019
Eckert & Ziegler to supply radioisotopes to Alpha Tau
Berlin
Eckert & Ziegler AG (ISIN DE0005659700) yesterday signed a multi-year supply agreement with Alpha Tau Medical (Tel Aviv, Israel) for the supply of Thorium-228. The radioisotope is used for the production of Alpha DaRT, a new innovative therapy for the treatment of a variety of solid tumors. … Read more
26/08/2019
Additional production capacities for Gallium-68-Generators released by supervisory authorities
Berlin
Eckert & Ziegler AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, has been given the manufacturing authorization for additional production lines for its Ge-68/Ga-68-generators (GalliaPharm®). The authorization has been given by the local … Read more
28/07/2019
Eckert & Ziegler to set up radiopharmaceutical production facility in China
Berlin
Eckert & Ziegler Strahlen- und Medizintechnik AG (S-DAX, ISIN DE0005659700) and Chengdu New Radiomedicine Technology Co. Ltd. (CNRT) have finalized an agreement about setting up, in Chengdu, PR China, a new production facility for radiopharmaceuticals used in the treatment of hepatocellular … Read more
04/10/2018
Eckert & Ziegler Takes Measures to Significantly Increase U.S. Availability of GalliaPharm® Pharmaceutical Grade Germanium-68/Gallium-68 Generators
Berlin, Germany
Eckert & Ziegler Strahlen-und-Medizintechnik AG (EZAG), through its wholly owned subsidiary Eckert & Ziegler Radiopharma GmbH (EZR), recently submitted to the U.S. Food and Drug Administration (U.S. FDA) an amendment of its Drug Master File (DMF) for its pharmaceutical grade … Read more
18/06/2018
Eckert & Ziegler is Manufacturing Partner for Bayer’s Innovative Targeted Thorium Conjugates in Europe
Berlin, Germany
Eckert & Ziegler AG, a specialist for scientific, medical, and industrial applications of radioisotopes, has been selected as manufacturing partner for clinical supply of Bayer’s innovative Targeted Thorium Conjugates (TTCs) in Europe. TTCs are a versatile, next-generation targeted alpha … Read more
24/10/2017
Eckert & Ziegler Awards Grants to Young Scientists in Nuclear Medicine
Berlin, Germany
This year’s Eckert & Ziegler Abstract Award went to five nuclear medicine specialists from Germany, Sweden and The Netherlands at the congress of the European Association of Nuclear Medicine (EANM) in Vienna. The prizes were awarded for research work in the fields of oncological … Read more
01/08/2017
GalliaPharm® Ge-68/Ga-68 generator receives approval for United Kingdom
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH has been granted marketing authorization (PL 46734/0001) for GalliaPharm® from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. This important milestone makes GalliaPharm® available as a medicinal … Read more
10/05/2017
Eckert & Ziegler invests in capacity expansion for its GalliaPharm® production line
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), signed a supply contract for components for a manufacturing line today, paving the way for the creation of additional capacities for its approved GalliaPharm® … Read more
04/05/2017
Eckert & Ziegler signs agreement to sell its cyclotron division to Alliance Medical
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler AG (ISIN DE 0005659700), signed an agreement today on the sale of its entire cyclotron division to Alliance Medical Ltd. Eckert & Ziegler will receive a payment in cash in the amount of € 13,0 million in return. The … Read more
23/03/2017
EANM/Eckert & Ziegler Abstract Award Submission Ends April 25, 2017
Vienna, Austria
Eckert & Ziegler is one of Europe’s largest manufacturers of isotope products. Together with the Association of Nuclear Medicine (EANM), the umbrella organization for nuclear medicine in Europe, it supports young scientists with travel grants to the annual EANM congress. Five awards of EUR … Read more
01/06/2016
NETSPOT ™ Gallium Ga 68 Dotatate Kit Approved By FDA Using The GalliaPharm® Ge-68/Ga-68 Generator As The Source Of Gallium-68
Advanced Accelerator Applications (AAA – The radiopharmaceutical company headquartered in SAINT-GENIS-POUILLY, France) have obtained approval from the US FDA for their diagnostic imaging NETSPOT ™ Gallium Ga 68 dotatate kit. The kit will be used for the labeling of 68Ga dotatate … Read more
02/02/2016
Eckert & Ziegler expands cooperation program with drug developers in the field of nuclear medicine
Berlin, Germany
Eckert & Ziegler AG, a specialist for isotope-based applications in medicine, science and industry, is expanding its cooperation program with promising drug developers in the field of nuclear medicine and will support Curasight, a spin-off based on research by the group of Professor Andreas … Read more
18/05/2015
IPSEN to acquire all shares in Octreopharm Sciences GmbH
Berlin, Germany
Berlin, 19 May 2015. Eckert & Ziegler Radiopharma GmbH (EZR) and a group of start-up investors have signed a purchase agreement with French pharmaceutical company IPSEN for all shares of Octreopharm Science GmbH (OPS), a drug development company located in Berlin-Buch. The deal, which is subject … Read more
03/12/2014
Eckert & Ziegler receives approval for Gallium-68 generator for cost-effective diagnosis of cancer
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) for its pharmaceutical 68Ge/68Ga generator for the German market. The 68Ge/68Ga generator is the world’s first, approved … Read more
26/06/2014
Eckert & Ziegler: European approval process for Gallium-68 generator successfully completed – world’s first authorization for new, inexpensive method for PET radiolabeling
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its pharmaceutical 68Ge/68Ga generators. This achievement marks the conclusion of a comprehensive decentralized evaluation procedure and the first time a … Read more
05/06/2012
Eckert & Ziegler obtains manufacturing authorization for pharmaceutical Gallium-68 generators
Berlin, Germany
Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler AG, has been given the manufacturing authorization for its pharmaceutical 68Ge/68Ga generators at the newly-built, GMP-compliant manufacturing facilities in Berlin. The authorization given by the local … Read more
Contact
Eckert & Ziegler
Radiopharma
Robert-Rössle-Straße 10
13125 Berlin
Germany
Radiopharma
Robert-Rössle-Straße 10
13125 Berlin
Germany
Get in touch
Do you have questions regarding any of our news? Contact us and we will get back to you as soon as possible.
Permission required
In order to submit your request it is required to load a 3rd-party service (Google Re-Captcha spam protection system). You current privacy settings prevent this from happening automatically. By clicking the button below you explicitly allow to temporarily (on this page) load 3rd party services.